Reach the investors backing rounds like this
Backed by Angelor, UI Investissement +6 more · verified emails and LinkedIn on Datapile
Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumours - EU-Startups
Brenus Pharma is a Lyon-based clinical-stage biotech startup focused on preventing cancer recurrence through innovative immunotherapy solutions. The company is developing a platform that engages the immune system to target hard-to-treat solid tumors, utilizing a novel dendritic cell-engager modality to convert cold tumors into responsive ones. This funding will help advance their next drug candidate and complete their Phase I program.
Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumours EU-Startups
| Nov 02, 2026 | Gallium Defense | $7 | Seed | France |
| Nov 02, 2026 | Fibraterre | $2.0M | Seed | France |
| Oct 23, 2026 | Mistral | $3.00B | Series D | France |
| Oct 18, 2026 | CarbonFarm | $7.8M | Series A | France |
You just read who funded Brenus Pharma. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.